# Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

> **NCT02100839** · PHASE1,PHASE2 · COMPLETED · sponsor: **LipimetiX Development, LLC** · enrollment: 52 (actual)

## Conditions studied

- Hypercholesterolemia
- Hyperlipoproteinemia Type II

## Interventions

- **DRUG:** AEM-28
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT02100839
- **Lead sponsor:** LipimetiX Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-11
- **Final completion:** 2014-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2015-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100839, "Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02100839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*